Literature DB >> 14769134

Expression of the splicing regulator polypyrimidine tract-binding protein in normal and neoplastic brain.

Ian E McCutcheon1, Stephen J Hentschel, Gregory N Fuller, Wei Jin, Gilbert J Cote.   

Abstract

Polypyrimidine tract-binding protein (PTB) is a nuclear factor that binds to the polypyrimidine tract of pre-mRNA introns, where it is associated with negative regulation of RNA splicing and with exon silencing. We have previously demonstrated that PTB expression is increased during glial cell transformation and that this increase correlates brain and in glial and neuronal tumors. Paraffin sections were stained by using a primary monoclonal antibody against PTB. Tissues that were analyzed included normal with changes in the RNA splicing of the fibroblast growth factor receptor 1. In this paper we examine the specific cellular distribution of PTB expression in normal brain (n = 2) and tumors of various types (low-grade astrocytoma, n = 2; anaplastic astrocytoma, n = 2; glioblastoma, n = 4; medulloblastoma, n = 4; central neurocytoma, n = 2; dysplastic gangliocytoma, n = 1; ganglioglioma, n = 1; paraganglioma, n = 1). In glial cell populations the majority of astrocytes and oligodendrocytes were negative, but occasional positively staining cells were observed. Strongly positive PTB staining was observed in ependymocytes, choroid plexus epithelium, microglia, arachnoid membrane, and adenohypophysis, and weak staining was found in the neurohypophysis. In all cases vascular endothelium and smooth muscle stained strongly. In tumor samples, intense positive nuclear staining was observed in transformed cells of low-grade astrocytoma, anaplastic astrocytoma, glioblastoma multiforme, medulloblastoma, paraganglioma, and the glial population of both ganglioglioma and dysplastic gangliocytoma (the neuronal cells of both were negative). In medulloblastoma, neoplastic neuronal cells were positive, as were other cell lineages. In normal brain, all neuron populations and pineocytes were negative for PTB. We conclude that although glial cells show derepression of PTB expression, a similar mechanism is absent in both nonneoplastic neurons and in most neuronally derived tumor cells. Strong upregulation of PTB expression in tumor cells of glial or primitive neuroectodermal origin suggests involvement of this protein in cellular transformation. Whether PTB affects splicing of RNAs critical to cellular transformation or proliferation is an important question for future research.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14769134      PMCID: PMC1871971          DOI: 10.1215/S1152851703000279

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  21 in total

Review 1.  Pre-mRNA splicing and human disease.

Authors:  Nuno André Faustino; Thomas A Cooper
Journal:  Genes Dev       Date:  2003-02-15       Impact factor: 11.361

Review 2.  Alternative pre-mRNA splicing and proteome expansion in metazoans.

Authors:  Tom Maniatis; Bosiljka Tasic
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

Review 3.  Fibroblast growth factors and their receptors.

Authors:  Z Galzie; A R Kinsella; J A Smith
Journal:  Biochem Cell Biol       Date:  1997       Impact factor: 3.626

4.  A 62,000 molecular weight spliceosome protein crosslinks to the intron polypyrimidine tract.

Authors:  J Wang; T Pederson
Journal:  Nucleic Acids Res       Date:  1990-10-25       Impact factor: 16.971

5.  Identification and purification of a 62,000-dalton protein that binds specifically to the polypyrimidine tract of introns.

Authors:  M A García-Blanco; S F Jamison; P A Sharp
Journal:  Genes Dev       Date:  1989-12       Impact factor: 11.361

6.  Fibroblast growth factor receptor-1 alpha-exon exclusion and polypyrimidine tract-binding protein in glioblastoma multiforme tumors.

Authors:  W Jin; I E McCutcheon; G N Fuller; E S Huang; G J Cote
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

7.  Redundant intronic repressors function to inhibit fibroblast growth factor receptor-1 alpha-exon recognition in glioblastoma cells.

Authors:  W Jin; E S Huang; W Bi; G J Cote
Journal:  J Biol Chem       Date:  1999-09-24       Impact factor: 5.157

8.  The use of antibodies to the polypyrimidine tract binding protein (PTB) to analyze the protein components that assemble on alternatively spliced pre-mRNAs that use distant branch points.

Authors:  J S Grossman; M I Meyer; Y C Wang; G J Mulligan; R Kobayashi; D M Helfman
Journal:  RNA       Date:  1998-06       Impact factor: 4.942

Review 9.  Embryonal central neuroepithelial tumors: current concepts and future challenges.

Authors:  S R Vandenberg; M M Herman; L J Rubinstein
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 10.  Medulloblastomas and related primitive neuroectodermal brain tumors of childhood recapitulate molecular milestones in the maturation of neuroblasts.

Authors:  J Q Trojanowski; T Tohyama; V M Lee
Journal:  Mol Chem Neuropathol       Date:  1992-10
View more
  26 in total

1.  Imaging the alternative silencing of FGFR2 exon IIIb in vivo.

Authors:  Vivian I Bonano; Sebastian Oltean; Robert M Brazas; Mariano A Garcia-Blanco
Journal:  RNA       Date:  2006-10-26       Impact factor: 4.942

2.  Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression.

Authors:  Roberto Ferrarese; Griffith R Harsh; Ajay K Yadav; Eva Bug; Daniel Maticzka; Wilfried Reichardt; Stephen M Dombrowski; Tyler E Miller; Anie P Masilamani; Fangping Dai; Hyunsoo Kim; Michael Hadler; Denise M Scholtens; Irene L Y Yu; Jürgen Beck; Vinodh Srinivasasainagendra; Fabrizio Costa; Nicoleta Baxan; Dietmar Pfeifer; Dominik von Elverfeldt; Rolf Backofen; Astrid Weyerbrock; Christine W Duarte; Xiaolin He; Marco Prinz; James P Chandler; Hannes Vogel; Arnab Chakravarti; Jeremy N Rich; Maria S Carro; Markus Bredel
Journal:  J Clin Invest       Date:  2014-05-27       Impact factor: 14.808

3.  Competition of PTB with TIA proteins for binding to a U-rich cis-element determines tissue-specific splicing of the myosin phosphatase targeting subunit 1.

Authors:  Supriya Shukla; Fabienne Del Gatto-Konczak; Richard Breathnach; Steven A Fisher
Journal:  RNA       Date:  2005-09-21       Impact factor: 4.942

4.  A role for polypyrimidine tract binding protein in the establishment of focal adhesions.

Authors:  Ivan Babic; Shalini Sharma; Douglas L Black
Journal:  Mol Cell Biol       Date:  2009-08-10       Impact factor: 4.272

5.  PTBP1-dependent regulation of USP5 alternative RNA splicing plays a role in glioblastoma tumorigenesis.

Authors:  Daisy I Izaguirre; Wen Zhu; Tao Hai; Hannah C Cheung; Ralf Krahe; Gilbert J Cote
Journal:  Mol Carcinog       Date:  2011-10-04       Impact factor: 4.784

Review 6.  RNA processing as an alternative route to attack glioblastoma.

Authors:  Fabiana Marcelino Meliso; Christopher G Hubert; Pedro A Favoretto Galante; Luiz O Penalva
Journal:  Hum Genet       Date:  2017-06-12       Impact factor: 4.132

7.  Polypyrimidine tract binding protein induces human papillomavirus type 16 late gene expression by interfering with splicing inhibitory elements at the major late 5' splice site, SD3632.

Authors:  Monika Somberg; Xiaomin Zhao; Monika Fröhlich; Magnus Evander; Stefan Schwartz
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

8.  Polypyrimidine tract-binding protein (PTB) differentially affects malignancy in a cell line-dependent manner.

Authors:  Chen Wang; John T Norton; Supurna Ghosh; Julie Kim; Kazuo Fushimi; Jane Y Wu; M Sharon Stack; Sui Huang
Journal:  J Biol Chem       Date:  2008-05-22       Impact factor: 5.157

9.  Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines.

Authors:  Hannah C Cheung; Tao Hai; Wen Zhu; Keith A Baggerly; Spiridon Tsavachidis; Ralf Krahe; Gilbert J Cote
Journal:  Brain       Date:  2009-06-08       Impact factor: 13.501

10.  Regulation of Numb isoform expression by activated ERK signaling.

Authors:  D Rajendran; Y Zhang; D M Berry; C J McGlade
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.